There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ACADIA Pharmaceuticals (ACAD – Research Report) and Alector (ALEC – Research Report) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals, with a price target of $23.00. The company’s shares closed last Monday at $17.73.
According to TipRanks.com, Butler is a 1-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.40.
See the top stocks recommended by analysts >>
Alector (ALEC)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Alector today and set a price target of $15.00. The company’s shares closed last Monday at $9.92, close to its 52-week low of $7.50.
According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alector with a $22.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
- UBS Sticks to Their Hold Rating for Salesforce (CRM)
- Air Products’ Middle East Merchant Industrial Gas Joint Venture, Abdullah Hashim Industrial Gases & Equipment Co. Ltd., Acquires Air Liquide’s Merchant Industrial Gases Business in the Kingdom of Saudi Arabia
- Payment of Shell plc second quarter 2022 interim dividend moved to Tuesday September 20, 2022
- B.Riley Financial Reaffirms Their Buy Rating on Spectrum Pharmaceuticals (SPPI)
- BofA Sees iPhone Pre-Order Numbers as Major Positive for (NASDAQ:AAPL)
